Genomics at JPM 2026

The biotech and pharma industries look to JPM each January to set the tone for the year ahead. Most attendees agreed that dealmaking is back—mainly smaller transactions rather than megadeals—and AI continues to make headlines (notably Nvidia and Lilly’s co-innovation AI lab). And everyone could agree on one thing: the weather was the best its been in years. 

The genomics industry was present with almost every NGS company presenting and several making significant announcements, though nothing earth-shattering. Element Biosciences teased a high-throughput benchtop sequencer, with more details coming in a webinar next month. Illumina highlighted its Billion Cell Atlas, a collaboration with AstraZeneca, Merck, and Lilly to accelerate AI-driven drug discovery. The company also surprised the community by naming Dr. Eric Green, former NHGRI director, as Chief Medical Officer. 10x Genomics outlined plans to move its technologies from research to clinical diagnostics, including developing a CLIA-certified lab to support clinical workflows.

Looking ahead to 2026, one thing is for sure: there is much more news to come. Attention now turns to AGBT in Orlando for the next wave of announcements. And Codex will bring you all of the news throughout the year. So stay tuned to this blog and sign up for our newsletter for the news and expert analysis from our consultants.

More insights in our bi-weekly newsletter. Subscribe for expert analysis and perspectives.